Immunomodulation of malignant melanoma by contact sensitizing agents

Ryan M. Trowbridge, Mario V. Mitkov, Mark R. Pittelkow, Devendra K. Agrawal

Research output: Contribution to journalReview article

8 Citations (Scopus)

Abstract

The importance of host defense against malignant melanoma is underlined by the use of immunomodulating agents as effective therapies. Diphencyprone and 2,4-dinitrochlorobenzene (DNCB) have been used successfully as contact sensitizing agents in this regard. Through haptenation of cell surface and cytoplasmic proteins, these agents trigger a CD8+ T-lymphocyte predominant allergic contact hypersensitivity response. Th17 cells may also play a critical role. The effectiveness of these agents at stimulating tumor defense may be limited to melanoma of the skin. Response to immunotherapy using diphencyprone and DNCB is governed by the immune status of the host, which is affected by tumor burden, UV light and age. Additionally, diphencyprone and DNCB elicit synergy with other methods of treatment and thus may be used as adjuncts. Two current prospective trials may aid in elucidating the impact that this treatment modality has on the prognosis and quality of life of patients with melanoma.

Original languageEnglish
Pages (from-to)63-76
Number of pages14
JournalExpert Review of Clinical Immunology
Volume10
Issue number1
DOIs
StatePublished - Jan 2014

Fingerprint

Dinitrochlorobenzene
Immunomodulation
Haptens
Melanoma
Th17 Cells
Contact Dermatitis
Ultraviolet Rays
Tumor Burden
Immunotherapy
Membrane Proteins
Therapeutics
Quality of Life
T-Lymphocytes
Skin
diphenylcyclopropenone
Neoplasms

All Science Journal Classification (ASJC) codes

  • Immunology and Allergy
  • Immunology

Cite this

Immunomodulation of malignant melanoma by contact sensitizing agents. / Trowbridge, Ryan M.; Mitkov, Mario V.; Pittelkow, Mark R.; Agrawal, Devendra K.

In: Expert Review of Clinical Immunology, Vol. 10, No. 1, 01.2014, p. 63-76.

Research output: Contribution to journalReview article

Trowbridge, Ryan M. ; Mitkov, Mario V. ; Pittelkow, Mark R. ; Agrawal, Devendra K. / Immunomodulation of malignant melanoma by contact sensitizing agents. In: Expert Review of Clinical Immunology. 2014 ; Vol. 10, No. 1. pp. 63-76.
@article{ef3ec25d53cb4ade979d6d4f1cd25214,
title = "Immunomodulation of malignant melanoma by contact sensitizing agents",
abstract = "The importance of host defense against malignant melanoma is underlined by the use of immunomodulating agents as effective therapies. Diphencyprone and 2,4-dinitrochlorobenzene (DNCB) have been used successfully as contact sensitizing agents in this regard. Through haptenation of cell surface and cytoplasmic proteins, these agents trigger a CD8+ T-lymphocyte predominant allergic contact hypersensitivity response. Th17 cells may also play a critical role. The effectiveness of these agents at stimulating tumor defense may be limited to melanoma of the skin. Response to immunotherapy using diphencyprone and DNCB is governed by the immune status of the host, which is affected by tumor burden, UV light and age. Additionally, diphencyprone and DNCB elicit synergy with other methods of treatment and thus may be used as adjuncts. Two current prospective trials may aid in elucidating the impact that this treatment modality has on the prognosis and quality of life of patients with melanoma.",
author = "Trowbridge, {Ryan M.} and Mitkov, {Mario V.} and Pittelkow, {Mark R.} and Agrawal, {Devendra K.}",
year = "2014",
month = "1",
doi = "10.1586/1744666X.2014.850415",
language = "English",
volume = "10",
pages = "63--76",
journal = "Expert Review of Clinical Immunology",
issn = "1744-666X",
publisher = "Expert Reviews Ltd.",
number = "1",

}

TY - JOUR

T1 - Immunomodulation of malignant melanoma by contact sensitizing agents

AU - Trowbridge, Ryan M.

AU - Mitkov, Mario V.

AU - Pittelkow, Mark R.

AU - Agrawal, Devendra K.

PY - 2014/1

Y1 - 2014/1

N2 - The importance of host defense against malignant melanoma is underlined by the use of immunomodulating agents as effective therapies. Diphencyprone and 2,4-dinitrochlorobenzene (DNCB) have been used successfully as contact sensitizing agents in this regard. Through haptenation of cell surface and cytoplasmic proteins, these agents trigger a CD8+ T-lymphocyte predominant allergic contact hypersensitivity response. Th17 cells may also play a critical role. The effectiveness of these agents at stimulating tumor defense may be limited to melanoma of the skin. Response to immunotherapy using diphencyprone and DNCB is governed by the immune status of the host, which is affected by tumor burden, UV light and age. Additionally, diphencyprone and DNCB elicit synergy with other methods of treatment and thus may be used as adjuncts. Two current prospective trials may aid in elucidating the impact that this treatment modality has on the prognosis and quality of life of patients with melanoma.

AB - The importance of host defense against malignant melanoma is underlined by the use of immunomodulating agents as effective therapies. Diphencyprone and 2,4-dinitrochlorobenzene (DNCB) have been used successfully as contact sensitizing agents in this regard. Through haptenation of cell surface and cytoplasmic proteins, these agents trigger a CD8+ T-lymphocyte predominant allergic contact hypersensitivity response. Th17 cells may also play a critical role. The effectiveness of these agents at stimulating tumor defense may be limited to melanoma of the skin. Response to immunotherapy using diphencyprone and DNCB is governed by the immune status of the host, which is affected by tumor burden, UV light and age. Additionally, diphencyprone and DNCB elicit synergy with other methods of treatment and thus may be used as adjuncts. Two current prospective trials may aid in elucidating the impact that this treatment modality has on the prognosis and quality of life of patients with melanoma.

UR - http://www.scopus.com/inward/record.url?scp=84893114796&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84893114796&partnerID=8YFLogxK

U2 - 10.1586/1744666X.2014.850415

DO - 10.1586/1744666X.2014.850415

M3 - Review article

C2 - 24308833

AN - SCOPUS:84893114796

VL - 10

SP - 63

EP - 76

JO - Expert Review of Clinical Immunology

JF - Expert Review of Clinical Immunology

SN - 1744-666X

IS - 1

ER -